Covering issues within the scientific community, In Sight is a deeply personal memoir of a woman’s experience transitioning a major scientific treatment from grassroots development to commercial breakthrough.
Covering issues within the scientific community, In Sight is a deeply personal memoir of a woman’s experience transitioning a major scientific treatment from grassroots development to commercial breakthrough.
Julia Levy has been a leader in the fields of science, education, and business. She served first as chief scientific officer and later as chief executive officer of QLT. During her tenure as CEO the company obtained regulatory approval for its macular degeneration treatment that resulted in the financial success of QLT Inc. She is an officer of the Order of Canada and has received a number of honorary degrees.
Inhaltsangabe
Foreword by Molly Shoichet 1. Waiting for the Other Shoe to Drop 2. Does Your Dog Always Sit in the Front Seat? 3. Where I Wanted to Be 4. Life in Bed-Sits 5. Woefully Outclassed 6. Whose Lab Do You Work In? 7. Earning My Stripes 8. Seeing the Light 9. Becoming Part of a Biotech Start-Up 10. Positioning QLT as a Photodynamic Therapy Company 11. Colleagues at American Cyanamid Come to Our Rescue 12. The Nation’s Blood Supply 13. PDT Is Different from Other Cancer Drugs 14. I Was Surprised and Not at All Pleased 15. Splitting Up 16. Failure Was Never an Option 17. Nothing Can Prepare You for the Torture of ODAC 18. Taking Big Steps in Our AMD Clinical Trials 19. An Open and Respectful Relationship 20. Our Work on Age-Related Macular Degeneration Is Her Legacy 21. We at QLT Were on Pins and Needles 22. People Couldn’t Stop Smiling 23. More Than a One-Trick Pony 24. Launching the Product and Hoping for No Unpleasant Surprises 25. Growing the Company 26. Time to Reflect 27. An Enormous Rush of Relief 28. A Biotech Company with a Lot of Money Is in Danger 29. I Thought These Problems Would Be Transient 30. Ongoing Headaches 31. He Felt Thoroughly Betrayed 32. Problems with Activist Shareholders 33. New Opportunity Acknowledgments About the Author Index
Foreword by Molly Shoichet 1. Waiting for the Other Shoe to Drop 2. Does Your Dog Always Sit in the Front Seat? 3. Where I Wanted to Be 4. Life in Bed-Sits 5. Woefully Outclassed 6. Whose Lab Do You Work In? 7. Earning My Stripes 8. Seeing the Light 9. Becoming Part of a Biotech Start-Up 10. Positioning QLT as a Photodynamic Therapy Company 11. Colleagues at American Cyanamid Come to Our Rescue 12. The Nation’s Blood Supply 13. PDT Is Different from Other Cancer Drugs 14. I Was Surprised and Not at All Pleased 15. Splitting Up 16. Failure Was Never an Option 17. Nothing Can Prepare You for the Torture of ODAC 18. Taking Big Steps in Our AMD Clinical Trials 19. An Open and Respectful Relationship 20. Our Work on Age-Related Macular Degeneration Is Her Legacy 21. We at QLT Were on Pins and Needles 22. People Couldn’t Stop Smiling 23. More Than a One-Trick Pony 24. Launching the Product and Hoping for No Unpleasant Surprises 25. Growing the Company 26. Time to Reflect 27. An Enormous Rush of Relief 28. A Biotech Company with a Lot of Money Is in Danger 29. I Thought These Problems Would Be Transient 30. Ongoing Headaches 31. He Felt Thoroughly Betrayed 32. Problems with Activist Shareholders 33. New Opportunity Acknowledgments About the Author Index
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
